This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
by Zacks Equity Research
Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell therapy achieved an overall response rate of 90% in patients with a rare form of blood cancer.
JNJPositive Net Change ABBVPositive Net Change BGNEPositive Net Change MBIONegative Net Change
biotechs cell-therapy medical pharmaceuticals
OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
by Zacks Equity Research
Two late-stage studies, which evaluated Ovid Therapeutics' (OVID) experimental drug for two forms of epilepsy, fail to meet their primary endpoints.
HRTXPositive Net Change OVIDPositive Net Change TAKPositive Net Change ARQTPositive Net Change
biotechs medical
Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals
by Zacks Equity Research
Aerovate's (AVTE) shares plunge 93% as its lead candidate, AV-101, fails to meet the primary and secondary endpoints in the phase IIb/III study to treat pulmonary arterial hypertension patients.
CGENPositive Net Change ANVSNegative Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine
by Zacks Equity Research
Novavax (NVAX) seeks FDA???s approval to update its COVID-19 vaccine for the 2024-2025 fall season against current circulating strains, including KP.2 and KP.3.
SNYPositive Net Change PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study
by Zacks Equity Research
Roche's (RHHBY) Columvi significantly extends survival in patients with relapsed or refractory diffuse large B-cell lymphoma in the phase III STARGLO study.
RHHBYPositive Net Change LGNDPositive Net Change NERVPositive Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Amgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment
by Zacks Equity Research
Amgen's (AMGN) Blincyto is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-ALL in the consolidation phase, regardless of MRD status.
AMGNNegative Net Change LGNDPositive Net Change TWSTPositive Net Change ANVSNegative Net Change
biotechs
Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
by Zacks Equity Research
Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.
VRTXNegative Net Change EDITPositive Net Change CRSPPositive Net Change ALXOPositive Net Change
biotechnology biotechs crispr gene-editing gene-therapy medical pharmaceuticals
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
by Zacks Equity Research
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro
by Zacks Equity Research
The FDA approves Bristol Myers' (BMY) cancer drug Augtyro for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
BMYNegative Net Change LGNDPositive Net Change NERVPositive Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Shattuck (STTK) Announces Positive Interim Data on Cancer Drug
by Zacks Equity Research
Shattuck (STTK) will now focus on higher-risk myelodysplastic syndromes and TP53 mutant acute myeloid leukemia indications for lead candidate SL-172154, following encouraging interim data from the phase IB dose expansion study.
LGNDPositive Net Change NERVPositive Net Change ALXOPositive Net Change STTKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Enzo Biochem (ENZ) Q3 Earnings Improve Y/Y, Gross Margin Up
by Zacks Equity Research
Enzo Biochem's (ENZ) overall topline benefits from revenue growth in the majority of its geographic regions.
biotechs earnings medical
Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
by Zacks Equity Research
Intellia's (NTLA) lead genome-editing candidate, NTLA-2001 being developed to treat transthyretin (ATTR) amyloidosis, holds promise. Other pipeline candidates are also progressing well.
REGNNegative Net Change NTLAPositive Net Change ALGSPositive Net Change ACRVPositive Net Change
biotechs
Repligen (RGEN) Promotes CCO, Shares Fall on Leadership Change
by Zacks Equity Research
Repligen (RGEN) appoints Olivier Loeillot as the company's new president and chief executive officer, effective from Sep 1, 2024. Stock falls on the news.
RGENPositive Net Change RAPTPositive Net Change ALGSPositive Net Change ACRVPositive Net Change
biotechs
Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
by Zacks Equity Research
Initial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.
RNAPositive Net Change HRTXPositive Net Change MRNSPositive Net Change ARQTPositive Net Change
biotechs medical
Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug
by Zacks Equity Research
Following a fruitful meeting with the FDA, Ultragenyx (RARE) plans to seek accelerated approval for UX111 for the treatment of Sanfilippo syndrome type A.
RAREPositive Net Change NERVPositive Net Change ALGSPositive Net Change ACRVPositive Net Change
biotechs
FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D
by Zacks Equity Research
Following the label expansion, AstraZeneca's (AZN) Farxiga is now approved to improve glycemic control in patients aged 10 years and older with T2D. It was previously approved for such use in adults.
AZNPositive Net Change LLYPositive Net Change HRTXPositive Net Change ARQTPositive Net Change
biotechs medical pharmaceuticals
Simulations Plus (SLP) Buys Pro-ficiency Holdings for $100M
by Zacks Equity Research
Simulation Plus (SLP) acquires Pro-ficiency from QHP Capital for $100 million in an all-cash transaction.
NVDAPositive Net Change SLPPositive Net Change MSINegative Net Change ANETPositive Net Change
biotechnology biotechs computers pharmaceuticals tech-stocks
Ultragenyx (RARE) Posts New Data From Bone Disease Study
by Zacks Equity Research
Ultragenyx's (RARE) pipeline candidate setrusumab shows sustained reductions in fracture rates in patients with osteogenesis imperfecta in new data from the Orbit study.
RAREPositive Net Change NERVPositive Net Change MRNSPositive Net Change ACRVPositive Net Change
biotechs
Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug
by Zacks Equity Research
Viridian (VRDN) intends to initiate two late-stage studies on its experimental thyroid eye disease drug this August. Top-line data from both studies are expected in first-half 2026
AMGNNegative Net Change HRTXPositive Net Change ARQTPositive Net Change VRDNPositive Net Change
biotechs medical
Regeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion
by Zacks Equity Research
The FDA approves label expansion of Regeneron (REGN) and Sanofi's Kevzara for the treatment of polyarticular juvenile idiopathic arthritis.
REGNNegative Net Change SNYPositive Net Change NERVPositive Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Moderna (MRNA) COVID-Flu Combo Jab Meets Late-Stage Study Goal
by Zacks Equity Research
Data from a late-stage study shows that Moderna's (MRNA) experimental COVID-19-influenza combination vaccine generates higher immune responses when compared to co-administered licensed flu and COVID vaccines.
PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data
by Zacks Equity Research
Structure Therapeutics (GPCR) stock sees an upside on positive top-line data from a phase IIa obesity study as well as a capsule-to-tablet PK study on its obesity candidate, GSBR-1290.
NVOPositive Net Change LLYPositive Net Change AMGNNegative Net Change GPCRPositive Net Change
biotechs
Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
by Zacks Equity Research
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
CGENPositive Net Change APLSPositive Net Change ANVSNegative Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Eli Lilly (LLY) Alzheimer's Drug Donanemab Gets FDA Panel Nod
by Zacks Equity Research
Eli Lilly (LLY) Alzheimer's disease drug, donanemab, receives Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) recommendation.
BIIBPositive Net Change LLYPositive Net Change PRTAPositive Net Change
biotechs
Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up
by Zacks Equity Research
Geron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.
BMYNegative Net Change GERNPositive Net Change KRYSPositive Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals